Hannah Joseph Hospital Limited is a healthcare service provider operating a multi-speciality hospital in Tamil Nadu. The company earns revenue primarily from in-patient services, out-patient consultations, diagnostics, pharmacy sales, and surgical procedures. Its services cater to secondary and tertiary healthcare needs, including critical care, general medicine, surgery, and allied medical services, delivered through a centrally located hospital infrastructure supported by trained medical professionals.

The Company is led by Promoter, i.e.,Mosesjoseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 4,275.47 Lakh, ₹ 7,790.05 Lakh, ₹ 6,362.81 Lakh, and ₹ 5,489.68 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,165.02 Lakh, ₹ 2,051.96 Lakh, ₹ 1,797.75 Lakh, and ₹ 1,638.07 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 511.86 Lakh, ₹ 720.99 Lakh, ₹ 406.64 Lakh, and ₹ 101.06 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue  EPS of ₹ 4.32 and post-issue EPS of ₹ 3.18 for FY25. The pre-issue P/E ratio is 16.20x,while the post-issue P/E ratio is 22.04x against the Industry P/E ratio is 53.28x The company's ROE for FY25 is 14.77% and RoNW is 14.74% The Annualised EPS is ₹ 4.51x and P/E is ₹ 15.52x, These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of Hannah Joseph Hospital showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Hannah Joseph Hospital Limited. IPO for Listing gain or Long Term Purposes.